Celebrex may slow colon cancer

Aug 31, 2006

Two U.S. studies say Pfizer's painkiller Celebrex can slow the recurrence of polyps in the colon for those at a higher risk of developing colon cancer.

But they also caution about an increased risk of heart attacks and strokes from the medicine, reports the Wall Street Journal.

The findings of the studies are published in this week's edition of the New England Journal of Medicine. Celebrex is commonly taken to relieve arthritis pain.

An editorial in the medical journal said because of the cardiovascular risk, Celebrex, or its generic version, has "no role" in preventing cancer in those who don't face high risk of colon cancer, the report said. Early testing is recommended for discovering polyps so they can be removed.

A Pfizer expert was quoted as saying the cancer results are encouraging but added, "We do not recommend Celebrex in treating and preventing cancer." He said the medicine, however, remains an important treatment option for arthritis sufferers.

Copyright 2006 by United Press International

Explore further: World Health Organization policy improves use of medicines

add to favorites email to friend print save as pdf

Related Stories

When is a drug too risky to stay on the market?

Jun 30, 2010

(AP) -- The arthritis pill Vioxx was withdrawn but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to ...

Can Celebrex prevent cancer-causing colon polyps?

May 13, 2010

Rush University Medical Center is testing whether celecoxib, known by its brand name Celebrex, can help prevent the growth of precancerous polyps that form in the colon, rectum and small intestine of children with an inheritable ...

Recommended for you

World Health Organization policy improves use of medicines

4 minutes ago

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

The genetics of coping with HIV

4 minutes ago

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

User comments : 0